Nuclear receptors as targets in cardiovascular diseases

Nuclear Receptors as Drug Targets

Volumn 39, Issue , 2008, Pages 409-429

  Kolkhof, Peter ^a   Bärfacker, Lars ^a   Hillisch, Alexander ^a   Haning, Helmut ^a   Schäfer, Stefan ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Heart failure; Mineralocorticoid receptor; Peroxisome proliferator activated receptor ; Thyroid hormone receptors

Indexed keywords

CYTOLOGY;

CARDIO-VASCULAR DISEASE; HEART FAILURE; MINERALOCORTICOID RECEPTORS; NUCLEAR RECEPTORS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; THYROID HORMONE RECEPTOR;

CARDIOLOGY;

EID: 77956929370     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527623297.ch13     Document Type: Chapter

References (94)

1. Lim, P.O., Young, W.F. and MacDonald, T.M. (2001) A review of the medical treatment of primary aldosteronism. Journal of Hypertension, 19, 353-361.
2. Gordon, R.D., Klemm, S.A., Tunny, T.J. and Stowasser, M. (1994) Genetics of primary aldosteronism. Clinical and Experimental Pharmacology & Physiology, 21, 915-918.
3. Loh, K.C., Koay, E.S., Khaw, M.C., Emmanuel, S.C. and Young, W.F. Jr. (2000) Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. Journal of Clinical Endocrinology and Metabolism, 85, 2854-2859.
4. Rossi, E., Regolisti, G., Negro, A., Sani, C., Davoli, S. and Perazzoli, F. (2002) High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. American Journal of Hypertension, 15, 896-902.
5. Kagawa, C.M., Cella, J.A. and Van Arman, C.G. (1957) Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt. Science, 126, 1015-1016.
6. Liddle, G.W. (1957) Sodium diuresis induced by steroidal antagonists of aldosterone. Science, 126, 1016-1018.
7. Mann, N. (1963) Gynecomastia during therapy with spironolactone. Journal of the American Medical Association, 184, 778-780.
8. Corvol, P., Michaud, A., Menard, J., Freifeld, M. and Mahoudeau, J. (1975) Antiandrogenic effect of spirolactones:mechanism of action. Endocrinology, 97, 52-58.
9. Jeunemaitre, X., Chatellier, G., Kreft-Jais, C., Charru, A., DeVries, C., Plouin, P.F., Corvol, P. and Menard, J. (1987) Efficacy and tolerance of spironolactone in essential hypertension. American Journal of Cardiology, 60, 820-825.
10. de Gasparo, M., Joss, U., Ramjoue, H.P., Whitebread, S.E., Haenni, H., Schenkel, L., Kraehenbuehl, C., Biollaz, M. et al. (1987) Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. Journal of Pharmacology and Experimental Therapeutics, 240, 650-656.
11. Ulmann, A., Bertagna, C., Le Go, A., Husson, J.M., Tache, A., Sassano, P., Menard, J. and Corvol, P. (1985) Assessment of the antimineralocorticoid effect of RU 28318 in healthy men with induced exogenous and endogenous hypermineralocorticism. European Journal of Clinical Pharmacology, 28, 531-535.
12. Losert, W., Bittler, D., Buse, M., Casals-Stenzel, J., Haberey, M., Laurent, H., Nickisch, K., Schillinger, E. et al. (1986) Mespirenone and other 15, 16-methylene-17-spirolactones, a new type of steroidal aldosterone antagonists. Arzneimittelforschung, 36, 1583-1600.
13. Elger, W., Beier, S., Pollow, K., Garfield, R., Qing Shi, S. and Hillisch, A. (2003) Conception and pharmacodynamic profile of drospirenone. Steroids, 68, 891-905.
14. de Gasparo, M., Whitebread, S.E., Preiswerk, G., Jeunemaitre, X., Corvol, P. and Menard, J. (1989) Antialdosterones:incidence and prevention of sexual side effects. Journal of Steroid Biochemistry, 32, 223-227.
15. Garthwaite, S.M. and McMahon, E.G. (2004) The evolution of aldosterone antagonists. Molecular and Cellular Endocrinology, 217, 27-31.
16. Weinberger, M.H., Roniker, B., Krause, S.L. and Weiss, R.J. (2002) Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. American Journal of Hypertension, 15, 709-716.
17. Pitt, B., Zannad, F., Remme, W.J., Cody, R., Castaigne, A., Perez, A., Palensky, J. and Wittes, J. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Rand omized Aldactone Evaluation Study Investigators. New England Journal of Medicine, 341, 709-717.
18. Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S. et al. (2003) Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine, 348, 1309-1321.
19. Swedberg, K., Cleland, J., Dargie, H., Drexler, H., Follath, F., Komajda, M., Tavazzi, L., Smiseth, O.A. et al. (2005) Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. European Heart Journal, 26, 1115-1140.
20. Funder, J. (2005) Mineralocorticoidreceptor blockade, hypertension and heart failure. Nature Clinical Practice Endocrinology & Metabolism, 1, 4-5.
21. Eli Lilly & Co., WO 2005/066161.
22. Eli Lilly & Co., WO 2004/052847.
23. Eli Lilly & Co., WO 2004/067529.
24. Eli Lilly & Co., WO 2003/078394.
25. Neel, D.A., Brown, M.L., Lander, P.A., Grese, T.A., Defauw, J.M., Doti, R.A., Fields, T., Kelley, S.A. et al. (2005) 3,3-Bisaryloxindoles as mineralocorticoid receptor antagonists. Bioorganic & Medicinal Chemistry Letters, 15, 2553-2557.
26. Exelixis, Inc., WO 2006/076202.
27. Exelixis, Inc., WO 2006/012642.
28. Dainippon Sumitomo Pharma Co., Ltd, WO 2006/077821.
29. Ligand Pharmaceuticals, Inc., WO 2006/010142.
30. Bayer HealthCare AG, WO 2005/087740.
31. IRM LLC, WO 2006/066011.
32. Takeda Pharmaceutical Co. Ltd, WO2005/097118.
33. Kolkhof, P., Flamme, I., Figueroa Perez, L., Baerfacker, L., Hartmann, E., Rinke, M. and Schäfer, S. (2006) Cardiac and renal protection by a new mineralocorticoid receptor antagonist in salt-sensitive arterial hypertension. European Heart Journal, 27 (Suppl 1), 110.
34. Kolkhof, P., Jilg, V. and Schäfer, S. (2007) Pharmacological characterization of a mutant mineralocorticoid receptor responsible for severe, early-onset hypertension. Clinical Research in Cardiology, 96 (Suppl 1). P525.
35. Sap, J., Munoz, A., Damm, K., Goldberg, Y., Ghysdael, J., Leutz, A., Beug, H. and Vennstroem, B. (1986) The c-erb-A protein is a high-affinity receptor for thyroid hormone. Nature, 324, 635-640.
36. Shahrara, S., Drvota, V. and Sylven, C. (1999) Organ specific expression of thyroid hormone receptor mRNA and protein in different human tissues. Biological & Pharmaceutical Bulletin, 22, 1027-1033.
37. Trost, S.U., Swanson, E., Gloss, B., Wang-Iverson, D.B., Zhang, H., Volodarsky, T., Grover, G.J., Baxter, J.D. et al. (2000) The thyroid hormone receptor-β-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology, 141, 3057-3064.
38. Ye, L., Li, Y.-L., Mellström, K., Mellin, C., Bladh, L.-G., Koehler, K., Garg, N., Collazo, A.M.G. et al. (2003) Thyroid receptor ligand s. 1. Agonist ligands selective for the thyroid receptor β1. Journal of Medicinal Chemistry, 46, 1580-1588.
39. Franklyn, J.A., Daykin, J., Betteridge, J., Hughes, E.A., Holder, R., Jones, S.R. and Sheppard, M.C. (1993) Thyroxine replacement therapy and circulating lipid concentrations. Clinical Endocrinology, 38, 453-459.
40. Pachucki, J., Burmeister, L.A. and Larsen, P.R. (1999) Thyroid hormone regulates hyperpolarization-activated cyclic nucleotide-gated channel (HCN2) mRNA in the rat heart. Circulation Research, 85, 498-503.
41. Simonides, W.S., Thelen, M.H.M., Van der Linden, C.G., Muller, A. and Van Hardeveld, C. (2001) Mechanism of thyroid-hormone regulated expression of the SERCA genes in skeletal muscle:implications for thermogenesis. Bioscience Reports, 21, 139-154.
42. Gloss, B., Trost, S., Bluhm, W., Swanson, E., Clark, R., Winkfein, R., Janzen, K., Giles, W. et al. (2001) Cardiac ion channel expression and contractile function in mice with deletion of thyroid hormone receptor α or β. Endocrinology, 142, 544-550.
43. Sun, Z.-Q., Ojamaa, K., Nakamura, T.Y., Artman, M., Klein, I. and Coetzee, W. (2001) A thyroid hormone increases pacemaker activity in rat neonatal atrial myocytes. Journal of Molecular and Cellular Cardiology, 33, 811-824.
44. Iervasi, G., Pingitore, A., Landi, P., Raciti, M., Ripoli, A., Scarlattini, M., L'Abbate, A. and Donato, L. (2003) Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation, 107, 708-713.
45. Scanlan, T.S., Suchland, K.L., Hart, M.E., Chiellini, G., Huang, Y., Kruzich, P.J., Frascarelli, S., Crossley, D.A. et al. (2004) 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nature Medicine, 10, 638-642.
46. Nguyen, N.-H., Apriletti, J.W., Cunha Lima, S.T., Webb, P., Baxter, J.D. and Scanlan, T.S. (2002) Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. Journal of Medicinal Chemistry, 45, 3310-3320.
47. Baxter, J.D., Goede, P., Apriletti, J.W., West, B.L., Feng, W., Mellstrom, K., Fletterick, R.J., Wagner, R.L. et al. (2002) Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. Endocrinology, 143, 517-524.
48. Webb, P., Nguyen, N.-H., Chiellini, G., Yoshihara, H.A.I., Cunha Lima, S.T., Apriletti, J.W., Ribeiro, R.C.J., Marimuthu, A. et al. (2002) Design of thyroid hormone receptor antagonists from first principles. Journal of Steroid Biochemistry and Molecular Biology, 83, 59-73.
49. Chiellini, G., Nguyen, N.H., Apriletti, J.W., Baxter, J.D. and Scanlan, T.S. (2002) Synthesis and biological activity of novel thyroid hormone analogues: 50-aryl substituted GC-1 derivatives. Bioorganic and Medicinal Chemistry, 10, 333-346.
50. Pantos, C., Mourouzis, I., Malliopoulou, V., Paizis, I., Tzeis, S., Moraitis, P., Sfakianoudis, K., Varonos, D.D. et al. (2005) Dronedarone administration prevents body weight gain and increases tolerance of the heart to ischemic stress: a possible involvement of thyroid hormone receptor α1. Thyroid, 15, 16-23.
51. Adamson, C., Maitra, N., Bahl, J., Greer, K., Klewer, S., Hoying, J. and Morkin, E. (2004) Regulation of gene expression in cardiomyocytes by thyroid hormone and thyroid hormone analogs 3,5-diiodothyropropionic acid and CGS 23425 [N-[3,5-dimethyl-4-(4'-hydroxy-3'-isopropylphenoxy)-phenyl]-oxamic acid]. Journal of Pharmacology and Experimental Therapeutics, 311, 164-171.
52. Chiellini, G., Apriletti, J.W., Yoshihara, H.A., Baxter, J.D., Ribeiro, R.C. and Scanlan, T.S. (1998) A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chemistry & Biology, 5, 299-306.
53. Stephan, Z.F., Yurachek, E.C., Sharif, R., Wasvary, J.M., Leonards, K.S., Hu, C.W., Hintze, T.H. and Steele, R.E. (1996) Demonstration of potent lipid-lowering activity by a thyromimetic agent devoid of cardiovascular and thermogenic effects. Atherosclerosis, 126, 53-63.
54. Underwood, A.H., Emmett, J.C., Ellis, D., Flynn, S.B., Leeson, P.D., Benson, G.M., Novelli, R., Pearce, N.J. et al. (1986) A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity. Nature, 324, 425-429.
55. Yoshihara, H.A.I., Apriletti, J.W., Baxter, J.D. and Scanlan, T.S. (2003) Structural determinants of selective thyromimetics. Journal of Medicinal Chemistry, 46, 3152-3161.
56. Ichikawa, K., Miyamoto, T., Kakizawa, T., Suzuki, S., Kaneko, A., Mori, J., Hara, M., Kumagai, M. et al. (2000) Mechanism of liver-selective thyromimetic activity of SK&F L-94901: evidence for the presence of a cell-type-specific nuclear iodothyronine transport process. Journal of Endocrinology, 165, 391-397.
57. Kissei Pharmaceutical Co., Ltd, EP 1471049A1, (2004).
58. Hayashi, M., Tamura, T., Kuroda, J., Ohnota, H., Shibata, N., Akahane, M., Kashida, Y. and Mitsumori, K. (2005) Different inhibitory effects in the early and late phase of treatment with KAT-681, a liver-selective thyromimetic, on rat hepatocarcinogenesis induced by 2-acetylaminofluorene and partial hepatectomy after diethylnitrosamine initiation. Toxicological Sciences, 84, 22-28.
59. Issemann, I. and Green, S. (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature, 347, 645-650.
60. Lalwani, N.D., Reddy, M.K., Qureshi, S.A., Sirtori, C.R., Abiko, Y. and Reddy, J.K. (1983) Evaluation of selected hypolipidemic agents for the induction of peroxisomal enzymes and peroxisome proliferation in the rat liver. Human Toxicology, 2, 27-48.
61. Karbowska, J., Kochan, Z. and Smolenski, R.T. (2003) Peroxisome proliferator-activated receptor α is downregulated in the failing human heart. Cellular& MolecularBiologyLetters, 8, 49-53.
62. Iemitsu, M., Miyauchi, T., Maeda, S., Tanabe, T., Takanashi, M., Irukayama-Tomobe, Y., Sakai, S., Ohmori, H. et al. (2002) Aging-induced decrease in the PPAR-α level in heart is improved by exercise testing. American Journal of Physiology.Heart and Circulatory Physiology, 283, H1750-H1760.
63. Berger, J. and Moller, D.E. (2002) The Mechanism of action of PPARs. Annual Review of Medicine, 53, 409-435.
64. Chinetti-Gbaguidi, G., Fruchart, J.-C. and Staels, B. (2005) Therapeutical effects of PPAR agonists assessed by biomarker modulation. Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals, 10 (Suppl 1), S30.
65. Chinetti, G., Fruchart, J.C. and Staels, B. (2000) Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflammation Research, 49, 497-505.
66. Ichihara, S., Obata, K., Yamada, Y., Nagata, K., Noda, A., Ichihara, G., Yamada, A., Kato, T. et al. (2006) Attenuation of cardiac dysfunction by a PPAR-α agonist is associated with downregulation of redox-regulated transcription factors. Journal of Molecular and Cellular Cardiology, 41, 318-329.
67. Ogata, T., Miyauchi, T., Sakai, S., Takanashi, M., Irukayama-Tomobe, Y. and Yamaguchi, I. (2004) Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-α activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kB pathway. Journal of the American College of Cardiology, 43, 1481-1488.
68. Sandner, P., Klein, M., Albrecht, B., Hartmann, E., Schäfer, S. and Hütter, J. (2006) Activation of PPAR-α reduces cardiac and renal end-organ damage in salt sensitive hypertension. European Heart Journal, 27 (Suppl 1), 2925.
69. Albrecht, B., Klein, M., Sandner, P., Golz, S., Hütter, J. and Schäfer, S. (2006) Activation of peroxisome proliferatoractivated receptor-α (PPARα) ameliorates post myocardial infarction heart failure in the rat: prevention of cardiac remodeling. European Heart Journal, 27 (Suppl 1), 437.
70. Willson, T.M., Brown, P.J., Sternbach, D.D. and Henke, B.R. (2000) The PPARs: from orphan receptors to drug discovery. Journal of Medicinal Chemistry, 43, 527-550.
71. Nissen, S.E. and Wolski, K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine, 356, 2457-2471.
72. Drew, B.G. and Calkin, A.C. (2007) Drug evaluation: K-111, an insulin-sensitizing peroxisome proliferators activated receptor α agonist. Current Opinion in Investigational Drugs, 8, 324-330.
73. Nissen, S.E., Nicholls, S.J., Wolski, K., Howey, D.C., McErlean, E., Wang, M..-D., Gomez, E.V. and Russo, J.M. (2007) Effects of a potent and selective PPAR-α agonist in patients with atherogenic dyslipidemia or hypercholesterolemia. Journal of the American Medical Association, 297, 1362-1373.
74. Mellanby, E. (1919) An experimental investigation on rickets. Lancet, 1, 407-412.
75. Lind, L., Lithell, H., Skarfors, E., Wide, L. and Ljunghall, S. (1988) Reduction of blood pressure by treatment with alphacalcidol. Acta Medica Scand inavica, 223, 211-217.
76. Lind, L., Wengle, B., Wide, L. and Ljunghall, S. (1989) Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. American Journal of Hypertension, 2, 20-25.
77. Shane, E., Mancini, D., Aaronson, K., Silverberg, S.J., Seibel, M.J., Addesso, V. and McMahon, D.J. (1997) Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. American Journal of Medicine, 103, 197-207.
78. Park, C.W., Oh, Y.S., Shin, Y.S., Kim, C.M., Kim, Y.S., Kim, S.Y., Choi, E.J., Chang, Y.S. et al. (1999) Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. American Journal of Kidney Diseases, 33, 73-81.
79. 3 is a negative endocrine regulator of the renin-angiotensin system. Journal of Clinical Investigation, 110, 229-238.
80. Kong, J. and Li, Y.C. (2003) Effect ofANGII type I receptor antagonist and ACE inhibitor on vitamin D receptor-null mice. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 285, R255-R261.
81. 3. Journal of Biological Chemistry, 269, 4934-4939.
82. Xiang, W., Kong, J., Chen, S., Cao, L.P., Qiao, G., Zheng, W., Liu, W., Li, X., Gardner, D.G. and Li, Y.C. (2005) Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. American Journal of Physiology. Endocrinology and Metabolism, 288, E125-E132.
83. Carlberg, C. and Mouriño, A. (2003) New vitamin D receptor ligand s. Expert Opinion on Therapeutic Patents, 13, 761-772.
84. Wagner, J., Dechow, C., Morath, C., Lehrke, I., Amann, K., Waldherr, R., Floege, J. and Ritz, E. (2000) Retinoic acid reduces glomerular injury in a rat model of glomerular damage. Journal of the American Society of Nephrology, 11, 1479-1487.
85. Dechow, C., Morath, C., Peters, J., Lehrke, I., Waldherr, R., Haxsen, V., Ritz, E. and Wagner, J. (2001) Effects of alltrans retinoic acid on renin-angiotensin system in rats with experimental nephritis. American Journal of Physiology. Renal Physiology, 281, F909-F919.
86. Lelievre-Pegorier, M., Vilar, J., Ferrier, M.L., Moreau, E., Freund, N., Gilbert, T. and Merlet Benichou, C. (1998) Mild vitamin A deficiency leads to inborn nephron deficit in the rat. Kidney International, 54, 1455-1462.
87. Merlet-Bénichou, C. (1999) Influence of fetal environment on kidney development. International Journal of Developmental Biology, 43, 453-456.
88. Schaier, M., Liebler, S., Schade, K., Shimizu, F., Kawachi, H., Grone, H.J., Chandraratna, R., Ritz, E. et al. (2004) Retinoic acid receptor α and retinoid X receptor specific agonists reduce renal injury in established chronic glomerulonephritis of the rat. Journal of Molecular Medicine (Berlin, Germany), 82, 116-125.
89. Terasaka, N., Hiroshima, A., Koieyama, T., Ubukata, N., Morikawa, Y., Nakai, D. and Inaba, T. (2003) T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Letters, 536, 6-11.
90. Joseph, S.B., McKilligin, E., Pei, L., Watson, M.A., Collins, A.R., Laffitte, B.A., Chen, M., Noh, G. et al. (2002) Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proceedings of the National Academy of Sciences of the United States of America, 99, 7604-7609.
91. Beyea, M.M., Heslop, C.L., Sawyez, C.G., Edwards, J.Y., Markle, J.G., Hegele, R.A. and Huff, M.W. (2007) Selective upregulation of LXR-regulated genes ABCA1, ABCG1, and APOE in macrophages through increased endogenous synthesis of 24(S),25-epoxycholesterol. Journal of Biological Chemistry, 282, 5207-5216.
92. Zelcer, N. and Tontonoz, P. (2006) Liver X receptors as integrators of metabolic and inflammatory signaling. Journal of Clinical Investigation, 116, 607-614.
93. Blaschke, F., Takata, Y., Caglayan, E., Collins, A., Tontonoz, P., Hsueh, W.A. and Tangirala, R.K. (2006) A nuclear receptor corepressor-dependent pathway mediates suppression of cytokine-induced Creactive protein gene expression by liver X receptor. Circulation Research, 99, e88-e99.
94. Mitro, N., Mak, P.A., Vargas, L., Godio, C., Hampton, E., Molteni, V., Kreusch, A. and Saez, E. (2007) The nuclear receptor LXR is a glucose sensor. Nature, 445, 219-223.